Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
I am Intramural Blog

Cutting-Edge Carriers Deliver Controllable Cancer Chemotherapy

New System Could Boost Treatment Effectiveness and Curb Side Effects

By Brandon Levy

Tuesday, April 2, 2019

nanovesicles

These microscopic drug-carrying packages, called nanovesicles, could allow doctors to precisely control the location and timing of chemotherapy delivery to tumor cells, according to new IRP research.

Cancer kills more than half a million men, women, and children each year in the U.S, and chemotherapy is only slightly more discriminating than the disease it treats. As a result, many cancer treatments kill cells throughout the body and cause severe side effects. New IRP research could solve this problem by creating a way to release those toxic compounds only when and where doctors desire.1

Recent revolutions in materials science allow researchers to manipulate materials at the level of individual molecules and atoms. Scientists take advantage of these breakthroughs to create methods of controlling the location, timing, and dosage of drug administration in the body.

Such techniques would be a particular boon to cancer patients because chemotherapy medications are toxic to both tumor cells and certain healthy cells. As a result, when those drugs are administered through traditional means and allowed to circulate throughout the entire body, they produce severe side effects. If the drugs could somehow be contained until they reach a tumor, the treatment would be both more effective and less harmful to the rest of the body.

“Over the past decade, significant research efforts have focused on designing nanomaterials whose properties and, therefore, behavior are regulated in a programmable fashion,” says IRP senior investigator Xiaoyuan ‘Shawn’ Chen, Ph.D., the new study’s senior author. “The challenge is to design and synthesize a drug delivery system that is sensitive to both tumor-specific internal stimuli like pH and external stimuli like heat or a magnetic field.”

In their new study, Dr. Chen and his team did just that. Their cutting-edge drug delivery system relies on two separate ‘logic gates,’ each of which acts as a safety switch to prevent the release of a drug unless a particular condition is fulfilled. Similar methods have been designed in the past that use one logic gate,2,3 but Dr. Chen’s is the first to use two.

“Two logic gates can achieve more accurate and controllable drug delivery and release,” he explains. “Drug release can only be carried out under the condition that multiple internal and external stimuli are satisfied simultaneously, so as to reduce drug toxicity and achieve targeted release.”

Dr. Chen’s treatment approach uses specially designed, microscopic packages called nanovesicles filled with a modified chemotherapy drug, which is composed of two molecules of the cancer drug doxorubicin connected to a dye molecule that heats up when it absorbs near-infrared light. Just like many traditional chemotherapies, the nanovesicles are injected into a vein and travel throughout the body, including to the tumor. The first logic gate is unlocked when a clinician shines a laser of near-infrared light into the tumor. When the laser hits the nanovesicles sitting amongst the cancer cells, it heats up the dye attached to the doxorubicin. The elevated temperature then causes another chemical inside the nanovesicles to break down and release unstable, highly reactive atoms called free radicals. The free radicals react with the nanovesicle’s shell, which is made of a material that degrades when it encounters free radicals.

Once the vesicle has disintegrated, the modified chemotherapy drug spills out into the tumor. At this point, the second logic gate is tripped by the acidic environment in the tumor, which breaks down the special chemical bond that connects the doxorubicin drug to the heat-generating dye molecule. Once unleashed, the drug is able to wreak havoc on the tumor.

Numerous experiments showed that the drug delivery system worked just as Dr. Chen’s team designed it to, preventing the release of the chemotherapy except when the nanovesicles were exposed to conditions warmer and more acidic than those typically found in the human body. Moreover, the drug delivery method markedly reduced the size of tumors in mice and prolonged the animals’ lives while causing minimal damage to the rest of their bodies.

Dr. Chen’s team must now conduct further tests with different types of tumors. The group also plans to scale up their method for creating the specially designed nanovesicles, as well as explore other ways besides a laser to trigger the drug’s release, since lasers can have difficulty reaching tumors in certain parts of the body.

“It is a promising drug delivery and drug release system,” Dr. Chen says. “It can control drug release more accurately and improve the therapeutic effect while reducing the toxic and side effects of chemotherapy drugs.”

Subscribe to our weekly newsletter to stay up-to-date on the latest breakthroughs in the NIH Intramural Research Program.

References:

[1] A Logic-Gated Modular Nanovesicle Enables Programmable Drug Release for On-Demand Chemotherapy. Tang L, Yang Z, Zhou Z, Ma Y, Kiesewetter DO, Wang Z, Fan W, Zhu S, Zhang M, Tian R, Lang L, Niu G, Zhang X, Chen X. Theranostics. 2019 Feb 14;9(5):1358-1368. doi: 10.7150/thno.32106. eCollection 2019.

[2] A logic-gated nanorobot for targeted transport of molecular payloads. Douglas SM, Bachelet I, Church GM. Science. 2012 Feb 17;335(6070):831-4. doi: 10.1126/science.1214081.

[3] Engineered modular biomaterial logic gates for environmentally triggered therapeutic delivery. Badeau BA, Comerford MP, Arakawa CK, Shadish JA, DeForest CA. Nat Chem. 2018 Mar;10(3):251-258. doi: 10.1038/nchem.2917. Epub 2018 Jan 15.


Category: IRP Discoveries
Tags: cancer, chemotherapy, nanomedicine, tumor, Test Tube Tuesday

Related Blog Posts

  • Dying Tumor Cells Suppress Anti-Cancer Immune Response
  • African Ancestry May Influence Immune Response to Prostate Cancer
  • Inflammation Contributes to Cancer-Related Fatigue
  • Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer
  • Gene Editing Reveals Potential Cancer Treatment Target

This page was last updated on Tuesday, May 23, 2023

Blog menu

  • Contributing Authors
    • Anindita Ray
    • Brandon Levy
    • Devon Valera
    • Melissa Glim
  • Categories
    • IRP Discoveries
    • Profiles
    • Events
    • NIH History
    • IRP Life

Blog links

  • Subscribe to RSS feed

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search